Combined General Meeting 2011 - May 6, 2011

Sanofi-Aventis

Description

Combined General Meeting 2011 - May 6, 2011

Sujets

• Arts

Informations

• Publié par: ecomejex
• Nombre de lectures: 57
• Langue: Français
• Poids de l'ouvrage: 9 Mo

Extrait

Paris, May

6,

2011  

 

GENERAL MEETING

2011

                                     

This tneserpnoita contains forward‐looking statements as defined in the Private Securities Litigation Reform Act of  1995,   as   amended.   Forward‐looking   statements   are   statements   that   are   not   historical   facts. These   statements   include   projections   and   estimates   and   their   underlying   assumptions,   statements   regarding   plans,   objectives,   intentions   and   expectations   with   respect   to   future   financial   results,   events,   operations,   services,   product     development   and   potential,   and   statements   regarding   future   performance.   Forward‐looking   statements   are   generally   identified   by s   expects,   anticipates,   believes,   intends,   estimates,   plans and   similar       the   word expressions. Although   sanofi‐aventis management   believes   that   the   expectations   reflected   in   such   forward‐ g statements   are   reasonable,   investors   are   cautioned   that   forward‐looking   information   and   statements   ar   e   lookin   subject   to   various   risks   and   uncertainties,   many   of   which   are   difficult   to   predict   and   generally   beyond   the   control      of   sanofi‐aventis,   that   could   cause   actual   results   and   lopmentsedev   to   differ   materially   from   those   expressed   in,   or   implied   or   projected   by,   the   forward‐looking   information   and   statements.   These   risks   and   uncertainties   include   among   other   things,   the   uncertainties   inherent   in   research   and   neevmopl,etd   future   clinical   data   and   analysis,   including   post   marketing,   decisions   by   regulatory   authorities,   such   as   the   FDA   or   the   EMA,   regarding   whether   and   when   to   approve   any   drug,   device   or   biological   application   that   may   be   filed   for   any   such   product   candidates   as   well   as   their   decisions   regarding   labelling   and   other   matters   that   could   affect   the   availability   or   commercial   potential   of   such   products   candidates,   the   absence   of   guarantee   that   the   products   candidates   if   approved   will   be   commercially   successful,   the   future   approval   and   commercial   success   of   therapeutic   alternatives,   the   Groups   ability   to   benefit   from   external   growth   opportunities   as   well   as   those   discussed   or   identified   in   the   public   filings   with   the   SEC   and   the   AMF   made   by   sanofi‐aventis,   including   those   listed   under   Risk   Factors and   Cautionary   Statement   Regarding   Forward‐Looking   Statements in   sanofi‐aventis annual   report   on   Form   20‐F   for   the   year   1,   2010.   ended   December   3 Other   than   as   required   by   applicable   law,   sanofi‐aventis   does   n   ot   undertake   any     obligation   to   update   or   revise   any   forward‐looking   information   or   statements.

Forward Looking Statement

2

 

Chief  xec rvitucexEeciffO e ficerncial Of feianiFtnedhC , PcesireivutVie  eeimttn Coatiopens Com,rotceri

Introduction   &   Governance Ser   ge   Weinberg,    2010   Achie   vements   &   Outlook  Chri   stopher   A.   Viehbacher,   Financial   Pe   rformance  Jérô   me   Contamine,   E Compensati   on   Policy  Gér   ard   Van   Kemmel,   D Questions   &     Answers   Vote   o   n   the   Resolutions  

3

Agenda

     

Boe thf  oanrmaisrotceriD fo drahC

Introduction & Governance

Serge Weinberg

Chairman of the Board of Directors

An Independent and Diverse Board   

Current Post‐AGM composition composition  14directors  15directors  Half     of   t   he   directors   are    A   m   ajor   ity   ofindependent independent*(7/14) directors*(8/15)         Your   Board   will   exceed   the   quota    2women   set   by   law   for   2014,   while    3women,   i.e.   20% benefitting from   the   exceptional         capabilities   of   these   women           6non‐French   directors  7non‐French   directors,   i.e.   46%        

*According to the independence criteria in the AFEP‐MEDEF corporate governance code

As of today, there is no potential conflict of interest between the  directors   and   the   Company  

 

5    

 

 

 

Board   of   Directors  Sep   aration   of   the   offices   of   Chairman   and   Chief   Executive   Officer   (since   January   1,   2007)    Governance   method   chosen   by   the   Board   of   Directors  The   Cha   irman   organizes   and   oversees   the   Board   of   Directors  The   Cha   irman   is   a   bridge   between   the   Board   of   Directors   and   the   Companys   management,   as   well   as   with   the   Companys   shareholders  

ucitevO ffcire  itaro noht ffO e 6 paSe nna d CihfeE   ex fices   of Chairma

An Active and Engaged Board   



9   meetings   in   2010,   including   sever   al   artxiydrraone   meetings     related   to   the   Genzyme acquisition      During   2010,   the   Board   was   given   presentations   by   key   managers       (including   Executive   Committee     members)   about   the   business   lines     under   their   responsibility    The   chairman   of   each   specialist   

The   chairman   of   each   specialist    committee   reports   to   the   Board   on     that   committees   work

   

High   attendance   rate   among   directors: over   90%

 

7